The Original Investigation titled, “Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial,”1 published online in the December 2021 issue, included an error in the number of EXCLAIM sites in the abstract and the Methods section. The number has been changed from 40 to 39. This article has been corrected online.
Reference
- 1.Zhou C, Ramalingam SS, Kim TM, et al. Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: a phase 1/2 open-label nonrandomized clinical trial. JAMA Oncol. 2021;7(12):e214761. doi: 10.1001/jamaoncol.2021.4761 [DOI] [PMC free article] [PubMed] [Google Scholar]